Dr. Reddy’s (RDY) Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance, NOC, received from Health Canada on April 28th, 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy’s readiness to ensure patient access following approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada Nod
- Dr. Reddy’s Earnings Call: Growth vs. Margin Pain
- Dr. Reddy’s Unveils FY 2026 Results, Dividend and Board, Auditor Changes
- Dr. Reddy’s Files Q4 FY26 Audited Results Presentation with Exchanges
- Dr. Reddy’s posts audio of March-quarter 2026 earnings call for investors